SynAct Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:SYNACT Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
21 Mar 24	BuySEK 98,325	Thomas Boesen	Individual		14,250	SEK 6.90
21 Mar 24	SellSEK 144,900	Thomas Boesen	Individual		21,000	SEK 6.90

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.1%.

Top 18 shareholders own 48.93% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.6%	NBCD A/S	3,962,790	SEK 37.0m	0%	no data
9.08%	Heights Capital Management, Inc.	3,750,000	SEK 35.0m	0%	1.31%
5.46%	Thomas Ringberg	2,252,969	SEK 21.0m	0%	no data
5.23%	TJ Biotech Invest ApS	2,161,225	SEK 20.2m	0%	no data
4.11%	Nordnet AB (publ), Asset Management Arm	1,698,777	SEK 15.8m	0%	0.22%
3.63%	Ryan Quinn	1,500,000	SEK 14.0m	0%	no data
3.46%	Quantass Invest Aps	1,428,558	SEK 13.3m	0%	no data
2.81%	Goodwind Holding GmbH	1,161,777	SEK 10.8m	0%	no data
1.89%	Handelsbanken Asset Management	781,198	SEK 7.3m	0%	no data
1.67%	Bioinvest Sverige Ab	688,670	SEK 6.4m	0%	no data
0.81%	Thomas Jonassen	332,864	SEK 3.1m	0%	no data
0.76%	SEB Investment Management AB	311,951	SEK 2.9m	0%	no data
0.22%	FCG Fonder AB	91,386	SEK 852.6k	0%	0.01%
0.089%	Skandia Fonder AB	36,871	SEK 344.0k	0%	no data
0.045%	Thomas Boesen	18,604	SEK 173.6k	0%	no data
0.033%	Jeppe Ovlesen	13,825	SEK 129.0k	0%	no data
0.03%	Storebrand Fonder AB,	12,469	SEK 116.3k	0%	no data
0.0022%	State Street Global Advisors, Inc.	923	SEK 8.6k	12.7%	no data